Pfizer announced additional $2.5 billion in planned savings through 2029 as part of an expanded cost‑cutting program, with most of the savings expected to be realized between 2027 and 2029 across R&D, manufacturing, commercial operations, and the cost of goods sold.
The new $2.5 billion is split into roughly $1.0 billion in administrative and operational efficiency savings and $1.5 billion in manufacturing and supply‑chain optimizations, bringing Pfizer’s total targeted net cost savings to about $9.7–10+ billion by 2029.
Pfizer estimates about $4–4.3 billion in one‑time costs (including severance, digital enablement, and asset write‑downs) to achieve these savings, which it will book through 2029 while maintaining its 2026 profit outlook and focusing on non‑COVID growth drivers such as Eliquis and its obesity and oncology pipelines.
Sources:
Pfizer cuts $2.5B more across R&D, manufacturing in ...
Pfizer targets $2.5bn more in cost savings
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts
Pfizer repels Covid-19 sales tumble to raise 2026 guidance
Pfizer dépasse les prévisions de bénéfices et vise 2,5 ...
Pfizer Adds Another $2.5 Billion To Its Cost-Cutting Plan
Pfizer is no longer just about COVID; the company reports solid results 💰
Lennart Pedersen's Post - pfizer
Pfizer Reports Second-Quarter Results And Raises ...
Pfizer beats earnings estimates, targets $2.5 billion in ...
Pfizer Q2 2026 Earnings Beat Estimates; Non-COVID Revenue Surges 18% Operationally
Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B